Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16-50 years

Journal of Crohn's and Colitis

Volumn 9, Issue 1, 2015, Pages 41-49

  Kennedy, Nicholas A ^a   Clark, Annalie ^a   Walkden, Andrew ^a   Chang, Jeff C W ^a   Fascí Spurio, Federica ^a   Muscat, Martina ^a   Gordon, Brydon W ^a   Kingstone, Kathleen ^a   Satsangi, Jack ^a   Arnott, Ian D R ^a   Lees, Charlie W ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Crohn's disease; Diagnostic test; Faecal calprotectin; Inflammatory bowel disease; Sensitivity; Ulcerative colitis

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CALGRANULIN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL STUDY; COHORT ANALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROHN DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE REGISTRY; FECES ANALYSIS; FECES LEVEL; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GROUPS BY AGE; HOSPITAL DEPARTMENT; HUMAN; INFLAMMATORY BOWEL DISEASE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS; UNITED KINGDOM; CHEMISTRY; CLINICAL TRIAL; COLONOSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES; FOLLOW UP; INFLAMMATORY BOWEL DISEASES; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADOLESCENT; ADULT; COLONOSCOPY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; ROC CURVE; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84905784416     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2014.07.005     Document Type: Article

References (25)

1. Gisbert J.P., McNicholl A.G. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis 2009;41:56-66
2. Konikoff M.R., Denson L. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis 2006;12:524-534
3. Tibble J., Teahon K., Thjodleifsson B., Roseth A., Sigthorsson G., Bridger S., et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000;47:506-513
4. Schoepfer A.M., Trummler M., Seeholzer P., Seibold-Schmid B., Seibold F. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 2008;14:32-39
5. Bonnín Tomàs A., Vila Vidal M., Rosell Camps A. Fecal calprotectin as a biomarker to distinguish between organic and functional gastrointestinal disease. Rev Esp Enferm Dig 2007;99:689-693
6. Carroccio A., Iacono G., Cottone M., Di Prima L., Cartabellotta F., Cavataio F., et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem 2003;49:861-867
7. D'Incà R., Dal Pont E., Di Leo V., Ferronato A., Fries W., Vettorato M.G., et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis 2007;22:429-437
8. Otten C.M.T., Kok L., Witteman B.J.M., Baumgarten R., Kampman E., Moons K.G.M., et al. Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome. Clin Chem Lab Med 2008;46:1275-1280
9. Schoepfer A.M., Trummler M., Seeholzer P., Criblez D.H., Seibold F. Accuracy of four fecal assays in the diagnosis of colitis. Dis Colon Rectum 2007;50:1697-1706
10. Mowat C., Cole A., Windsor A., Ahmad T., Arnott I., Driscoll R., et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60:571-607
11. NICE Faecal calprotectin diagnostic tests to differentiate inflammatory bowel disease from irritable bowel syndrome [Internet]. [cited 2013 Mar 25]; available from http://guidance.nice.org.uk/DT/12 2013
12. Waugh N., Cummins E., Royle P., Kandala N.-B., Shyangdan D., Arasaradnam R., et al. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: a systematic review and economic [Internet]. 2013; 1-241. [Available from http://www.nice. org.uk/nicemedia/live/13789/64011/64011.pdf]
13. Von Roon A.C., Karamountzos L., Purkayastha S., Reese G.E., Darzi A.W., Teare J.P., et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 2007;102:803-813
14. Van Rheenen P.F., Van de Vijver E., Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010;341:c3369
15. Limburg P.J., Ahlquist D.A., Sandborn W.J., Mahoney D.W., Devens M.E., Harrington J.J., et al. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol 2000;95:2831-2837
16. Silverberg M.S., Satsangi J., Ahmad T., Arnott I.D., Bernstein C.N., Brant S.R., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19 Suppl. A:5-36
17. Lennard-Jones J.E. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989;170:2-6[discussion 16-9]
18. Drossman D.A. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006;130:1377-1390
19. Department of Health 2012-13 tariff information spreadsheet [Internet].[cited 2013 Mar 25]; available fromhttp://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/ DH_132654 2012
20. Newcombe R.G. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998;17:857-872
21. Simel D.L., Samsa G.P., Matchar D.B. Likelihood ratios with confidence: sample size estimation for diagnostic test studies. J Clin Epidemiol 1991;44:763-770
22. Van Rheenen P.F. Role of fecal calprotectin testing to predict relapse in teenagers with inflammatory bowel disease who report full disease control. Inflamm Bowel Dis 20121-8
23. Desai D., Faubion W.A., Sandborn W.J. Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther 2007;25:247-255
24. Pearson S., Whitehead S., Hutton J. Evidence review: value of calprotectin in screening out irritable bowel syndrome [Internet]. Cent. Evidence-based Purch.[cited 2013 Mar 25]; available fromhttp://nhscep.useconnect.co.uk/ CEPProducts/Catalogue.aspx?reportId=147 2010
25. Mindemark M., Larsson A. Ruling out IBD: estimation of the possible economic effects of pre-endoscopic screening with F-calprotectin. Clin Biochem 2012;45:552-555